PTC and Jazz Pharmaceuticals Among Latest Firms to Win EU Backing for Drugs
Zai Lab To Present Data From Phase 1 Trial Of DLL3-Targeted Antibody-Drug Conjugate ZL-1310 At 2025 ASCO Annual Meeting
Merus Says Petosemtamab In Combination With Pembrolizumab In 1L PD-L1+ R/M HNSCC Interim Clinical Data Selected For Poster Presentation At 2025 ASCO Annual Meeting
9 Health Care Stocks With Whale Alerts In Today's Session
RBC Capital Reiterates Outperform on PTC Therapeutics, Maintains $65 Price Target
PTC Therapeutics Analyst Ratings
Gene Therapy Developers Rise on Comments From FDA's Makary
Hertz Global And Webull Stocks Are Among Top Mid-Cap Gainers Last Week (Apr 14-Apr 18): Are The Others In Your Portfolio?
Executive Reshuffles: CAT, LMT, and APA
These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio?
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
FDA Staff Cuts Are Already Impacting Regulatory Work, Biotech Leaders Warn
Beyond The Numbers: 13 Analysts Discuss Avidity Biosciences Stock
Avidity Biosciences Analyst Ratings
Merus Analyst Ratings
Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday
Rhythm Pharmaceuticals Shares Are Trading Higher After Multiple Analysts Raised Their Price Targets on the Stock.
Needham Reiterates Buy on Rhythm Pharmaceuticals, Maintains $66 Price Target
Wells Fargo Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $91